Pulse Biosciences, Inc., a clinical-stage medical technology company headquartered in Hayward, California, disclosed in a US Securities and Exchange Commission filing that the company and several of its directors have received subpoenas from the SEC. According to Pulse, the SEC is seeking information about trading of the company’s stock in advance of the financing announcement made by the company in September 2017. Pulse says that it is cooperating with the investigation.
March 14, 2019
Medical technology company discloses SEC investigation
Related by Topic
New Post
SEC charges former medical technology executive with insider trading in Texas
October 3, 2024
News Alert
New Post
SEC obtains final judgments with members of complex insider trading scheme
September 30, 2024
News Alert
SEC reaches settlement with fifth member of an insider trading scheme
September 25, 2024
News Alert